Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Aneurysmal Subarachnoid Hemorrhage (aSAH): later-stage trial registry
1 of 2 indexed Aneurysmal Subarachnoid Hemorrhage (aSAH) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Aneurysmal Subarachnoid Hemorrhage (aSAH): 2 US clinical trials tracked, 1 recruiting.
Aneurysmal Subarachnoid Hemorrhage (aSAH) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Grace Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition aneurysmal-subarachnoid-hemorrhage-asah
OPEN 1 | RECR 50% | LATE 2 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Aneurysmal Subarachnoid Hemorrhage (aSAH) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Aneurysmal Subarachnoid Hemorrhage (aSAH) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Aneurysmal Subarachnoid Hemorrhage (aSAH) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage
Wright State University
NCT07116408
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
Grace Therapeutics
NCT05995405
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Aneurysmal Subarachnoid Hemorrhage (aSAH) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Aneurysmal Subarachnoid Hemorrhage (aSAH) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Aneurysmal Subarachnoid Hemorrhage (aSAH) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Aneurysmal Subarachnoid Hemorrhage (aSAH) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Grace Therapeutics sponsors the most Aneurysmal Subarachnoid Hemorrhage (aSAH) trials on record, review their full trial history before evaluating a specific study. See Grace Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Aneurysmal Subarachnoid Hemorrhage (aSAH) condition card totals 2 registered trials; most-linked intervention Nimotop 30 MG Oral Capsule; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.